Abstract:3642 Introduction: Necrosis is a common characteristic of cancer progression, and causes the release of DNA into the circulation. This cell death and release of DNA is due in part to uncontrolled tumor growth overwhelming the capacity of its supply of oxygen and nutrients. The DNA fragments released from spontaneous apoptosis of cancer cells can also enter the circulation and be detected in plasma. While plasma DNA level is likely to be a marker for cancer progression and treatment, the method for rapid and quantitative measurement of plasma DNA without extraction is not well developed. Recently, we have utilized QuantiGene 2.0 technology to develop a method that can sensitively measure the level of plasma DNA with potential for monitoring cancer progression and treatment. Methods: A novel assay based on QuantiGene 2.0 technology was developed. Several capture probes were designed to immobilize the plasma DNA on plate. The bound DNA was detected using several layers of amplifications, i.e. the label extender, preamplifier, amplifier and label probe conjugated with alkaline phosphatase. The substrate Lumigen APS-5 yields chemiluminescence (RLU), which is quantitatively related to the amount of bound DNA. The plasma DNA was measured in plasma sample from 1) normal adults; 2) patients with different diseases, including lymphoma, leukemia, liver cancer; 3) patients with autoimmune disease, such as systemic lupus erythematosus (SLE) which has antibody generated against autologous DNA; 4) pregnant subjects; and 5) leukemia patient that had received radiation for bone marrow transplantation (BMT). The significance of results was assessed. Results: The correlation co-efficient (R value) between RLU and plasma DNA concentration of our assay was 0.9996. While the normal adults had a very low level of plasma DNA, all the cancer patients (lymphoma, leukemia and liver cancer) had much higher (11-26 fold). The patients with SLE also had a high level of plasma DNA as did pregnant women. The leukemia patients who received TBI (1.65 Gy BID x 4 days) prior to BMT had a huge surge (about 140 times normal) of plasma DNA seen immediately after the first dose of total body radiation (TBI), and which remained high during the whole course of radiation. When TBI was stopped on day 6, the level gradually declined to the basal level on day 9. Conclusion: We have developed a highly sensitive method to determine the plasma DNA level. The method can be used for several clinical applications, and has potential for monitoring cancer progression and therapeutic effect. The value of this index will be tested in a large-scale clinical trial.

Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis.

The Detection of Plasma Soluble Podoplanin of Patients with Breast Cancer and Its Clinical Signification.

Development of a Sandwich ELISA for Evaluating Soluble PD-L1 (CD274) in Human Sera of Different Ages As Well As Supernatants of PD-L1+ Cell Lines

Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer

Elevated Expression of Podoplanin and Its Clinicopathological, Prognostic, and Therapeutic Values in Squamous Non-Small Cell Lung Cancer

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes

Diagnostic Plasma Small Extracellular Vesicles Mirna Signatures for Pancreatic Cancer Using Machine Learning Methods

Elevated Expression of Exosomal Microrna-21 As a Potential Biomarker for the Early Diagnosis of Pancreatic Cancer Using a Tethered Cationic Lipoplex Nanoparticle Biochip.

Expression Of Podoplanin In Sinonasal Squamous Cell Carcinoma And Its Clinical Significance

Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients

Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer

Blocking Podoplanin Inhibits Platelet Activation and Decreases Cancer-Associated Venous Thrombosis.

Blocking Podoplanin Suppresses Growth and Pulmonary Metastasis of Human Malignant Melanoma.

A sensitive method for quantitative measurement of plasma dna: a marker for cancer progression and treatment

Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma

Plasma S100p Level As A Novel Prognostic Marker of Metastatic Breast Cancer

Serum Exosomal Mirna-1226 As Potential Biomarker of Pancreatic Ductal Adenocarcinoma

Level of Soluble Programmed Death-1 Ligand 1 in Peripheral Blood of Patients with Advanced Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma and Its Clinical Implications

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy